This function is exclusive for Premium subscribers

  • DATABASE (45)

  • ARTICLES (22)

    • DATABASE (45)
    • ARTICLES (22)

Proxima Ventures was founded in 2016 in Shanghai. It manages both RMB and US dollar funds, worth around US$150m in total. The firm invests mainly in early-stage startups in the healthcare sector. It has invested in 18 companies and established six innovation centers to incubate medtech startups. 

Yueyin Venture Capital was founded in 2015 in Beijing. It manages total assets worth US$300m, with investments in 22 companies. The VC focuses mainly in the healthcare, pharmaceutical and biotech sectors. 

Haibang Fund was created in 2011 by Haibang Venture based in Hangzhou. Haibang Fund manages total assets worth US$360m with investments in 60 companies, four of which have gone public. Started by a group of overseas returnees and experienced investors, the VC focuses on startups founded by returnees from overseas.

Renhe Group was founded in Jiangxi Province by Yang Wenlong in 2001. The group, including its flagship listed Renhe Pharmacy, earned total sales revenue of RMB 11.23bn in 2018 with a year-on-year profit growth of 25%. The group comprises 20 subsidiaries dealing in cosmetics, household chemicals, pharmaceutical, medical supplies and equipment.

Junrun Capital was founded in 2009 in Ningbo, Zhejiang province. It's the largest private equity fund in Ningbo and specializes in M&A, equity and venture capital investments. So far, it has successfully exited seven deals out of a total of 21. Junrun has investment managers and researchers with backgrounds in science and technology. It has offices in Hangzhou, Shanghai, Shenzhen and the US. The company mainly seeks investment opportunities in sustainable materials, cleantech, agriculture, manufacture, biotechnology and the dotcom economy.

SFund, aka Guangzhou Industrial Investment Fund Management Co Ltd, was established in March 2013 by the Guangzhou Municipal Government to boost industrial upgrading in the city. Its business covers government fund management, private equity investment and venture capital investment.In July 2018, SFund became a subsidiary of Guangzhou City Construction Investment Group. The decision was made by the Guangzhou Municipal Government and the State-owned Assets Supervision and Administration Commission of the State Council.SFund has set up seven funds, managing total assets worth RMB 139bn. It has invested in 343 companies, 13 of which have become public-listed.

Founded in Beijing in 2015, Frees Fund is an asset management company with a portfolio valued at RMB 3.6bn. Frees primarily invests in early-stage startups in diverse sectors including fintech, education, healthcare, entertainment, hardware, intelligent manufacturing and SaaS. The VC is incorporated as Shanghai Ziyou Investment Management Co Ltd.

GF Qianhe is an equity investment company launched by GF Securities in May 2012. Incorporated as Guangfa Qianhe Investments Co Ltd, with a registered capital of RMB 500m, the company was one of the earliest alternative investment companies to gain approval from the Securities Commission of China. As of late 2018, GF Qianhe has invested in 86 equity-related projects, among which four have gone public. By the end of 2014, its total investment value reached almost RMB 2bn and revenues of over RMB 340m.

Founded in 2014, Prosperico Ventures targets the healthcare sector. The VC has invested in nearly 30 startups working on medical devices, pharmaceutical R&D, provision of medical services and precision medicine.

Shenzhen Guozhong Venture Capital Management Co., Ltd. (GZVCM) was founded in December 2015. Chief Partner and CEO Shi Anping previously served as vice president at Shenzhen Venture Capital Group. GZVCM is currently entrusted to operate the state-backed Small Medium Enterprises Development Fund, which has RMB 60bn under management.

Headquartered in Shanghai, FC Capital was founded in 2017 to focus on investments in China and the US. The VC mainly invests in medtech sectors like biotechnology, medical devices, medical services and health-related consumer products.

Baiyang Capital was founded in 2014 by BAHEAL Pharmaceutical Holdings Limited and several senior professionals in the pharmaceutical and healthcare fields. The investment management company operates multiple funds, targeting pharmaceutical and healthcare businesses.

Investing in hi-tech IT, advanced manufacturing and biotechnology sectors – key pillars of China’s innovation-focused economy since 2017 – the Beijing government-backed Beijing Zhongguancun Longmen Investment manages about RMB 10bn via its first fund of the same name. The firm is founded and led by Xu Jinghong, former Chairman of Tsinghua Holdings, the investment and tech/R&D transfer arm of China’s most prestigious science and research university, whose R&D capacity was ranked in the third place of China’s top 500 enterprises in 2018. The LPs of the fund include social security funds, Beijing’s municipal government and the Haidian District government. Its portfolio enterprises are generally ranked in the top three of their respective industries. Among them, Qi An Xin Technology, which is listed in Shanghai and one of China’s biggest cybersecurity companies; Joy Wing Mao, one of China’s major fruits supply chain companies. In October of 2020, it invested RMB 100m into Beijing Immunochina Pharmaceutical, which develops innovative gene and cell therapies for curing malignant tumors. Longmen also provides mentoring and other expertise and support to its investee startups, especially those that plan to seek public listing.

SoftBank announced its second Vision Fund of about $108bn in July 2019 to invest in technology startups across the world. SoftBank had originally planned to contribute $38bn to the new fund. However, its Vision Fund I was badly affected by the Covid-19 pandemic and losses resulting in lower valuations of its investments in Uber and WeWork.In February 2020, the Japanese conglomerate decided to inject more money into the Vision Fund II before raising new funds from other LPs. With $10bn committed to the second fund by the SoftBank Group, the new fund has now invested in 13 portfolio companies including co-leading the Series C round for XAG in November 2020.

Guangzhou Emerging Industry Development Fund (Emerging Fund) is a wholly-owned subsidiary of Guangzhou Industrial Investment Fund Management Co Ltd (SFund).It was found in line with the Guangzhou Municipal Government’s industrial upgrade strategy, with the aim of pooling capital, projects and talents together in Guangzhou. The Emerging Fund currently manages a set of government-guided funds and direct investment funds. It also invests in several state-level guidance funds on behalf of the municipal government. It mainly invests in emerging sectors in manufacturing, information technology, service sectors, seed and related industries.

Your payment was not successful.

Please make sure you have entered your payment details correctly. Or try again in a few moments.

small logo

The discount code you entered is invalid

Please make sure you have entered your discount code correctly. Or try again in a few moments.

Download successful.

Your sample has been sent. Please check your email.

By accessing and using and all pages within the domain (the “Website”), You accept and agree to have read, understood, accepted and agreed to be bound by the Terms of Use and Privacy Policy in full. If you disagree with all or any part of these Terms of Use and Privacy Policy, please do not use or continue any further use of this website. You acknowledge that you are aware that this Website contains an archive of existing content as at 31 December 2021 and is not being actively managed. We are under no obligation to update the content on this Website and, accordingly, no new content or articles will be posted to the Website after 31 December 2021.